Business Wire

TA Announces Advantive, a New Mission-Critical Software Provider for Specialty Manufacturing and Distribution Businesses

28.6.2022 16:13:00 EEST | Business Wire | Press release

Share

TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/

Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida.

Benoit de la Tour, an accomplished executive in the ERP and Supply Chain software space, has been named the CEO of Advantive. “I'm thrilled to join Advantive as CEO, working hand-in-hand with TA and ST6 to deliver increased customer value,” said Benoit. “Advantive was formed with a simple purpose— to drive sustainable growth for specialty manufacturing and distribution companies. We’re in a unique position, alongside our customers, to make a real impact. With Advantive’s packaging, ecommerce and delivery solutions, spanning raw resources to valuable products, we’re transforming the manufacturing and distribution lifecycle.”

“We are excited to partner with Benoit and ST6 as we build upon the strength of Advantive’s constituent businesses to create an overall market leader in ERP, MES and SPC software,” said Hythem El-Nazer, a Managing Director at TA. “Advantive’s software solutions modernize and optimize every aspect of the manufacturing and distribution lifecycle, from enhanced plant production, supply chain optimization and ecommerce, to managing quality and compliance. Advantive is changing the way business is done, and we are excited to support the business as it grows.”

Mark Friedman, a longtime, experienced software operating executive and investor, is the Executive Chairman of Advantive. Friedman, currently a Managing Director at ST6, was previously the founder and CEO of Accruent, a leading software company that disrupted the multi-billion-dollar facilities management and lease administration software market. “Now more than ever, our customers need the ability to rapidly adapt to global supply chain challenges, and to gain a competitive advantage,” said Friedman. “By combining the strengths of Advantive’s constituent companies, and delivering deep, purpose-built software, we believe we are positioned to drive transformational outcomes for our customers.’

About Advantive

Advantive is a market leader in mission-critical software for specialty manufacturing and distribution companies, offering purpose-built ERP, MES and SPC software solutions that meet the unique needs of our customers. Serving over 2,500 customers and operating in 8 countries, Advantive’s software solutions streamline complex processes, optimize operations visibility and throughput, and drive improved quality, profitability and revenue growth. Deeply embedded into key end-to-end workflows, Advantive’s software uses automation, seamless integration and real-time data to streamline plant scheduling, order management, quality control, sales order forecasting and pricing, ecommerce and delivery – making the complex, simple.

About TA

TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer, and business services – the firm invests in profitable, growing companies with opportunities for sustained growth and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .

About ST6

ST6 is an elite team of software operating executives that partner with private equity sponsors to transform software companies and accelerate value creation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA:
Jeff Sindone
Teneo

Jeff.Sindone@teneo.com
Mobile: (917) 224-7140

Maggie Benoit
TA
mbenoit@ta.com
Office: 617-598-6685

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release

Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release

QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye